Professor Paul Moss

Professor Paul Moss

Institute of Immunology and Immunotherapy
Director of Research and Knowledge Transfer, Professor of Haematology

Contact details

Institute of Immunology and Immunotherapy
University of Birmingham
Cancer Sciences Building
B15 2TT

Professor Moss is Professor of Haematology at the University of Birmingham and Director of Research and Knowledge Transfer in the College of Medicine.  He is an NIHR Senior Investigator and was previously Chair of the Infection and Immunity Board at the Medical Research Council and the Clinical and Translational Research Committee at Cancer Research UK.

In this video Paul Moss describes his career to date, his passion for his research and how it is helping to change the world, and how he enjoys working with postgraduate researchers from the UK and abroad.


  • M.A. Medical Sciences (University of Cambridge)
  • B.M. B.S. (University of Oxford)
  • Member of Royal College of Physicians UK
  • Fellow of Royal College of Pathologists
  • Ph.D
  • Fellow of the Academy of Medical Sciences


Teaching Programmes

MBChB Year 5, MBChB Year 4, MBChB Year 3, MBChB Year 2, MBChB Year 1, BMedSci 3, BMedSci 2, BMedSci 1, Clinical Oncology MSc/PG Dip

Teaching Activity 

Professor Moss makes substantial contributions to teaching both within the University of Birmingham and beyond. He was previously Programme Director of the Intercalated Bachelor in Medical Sciences (Clinical Sciences) which offers medical students the opportunity to undertake an 8 month research project during their undergraduate degree.


Research Themes

Haematology and Translational Immunology 

Research Activity

Professor Moss’s research is focussed around the application of translational immunological research in the study of human disease. His current research group includes clinical and non-clinical research scientists working on a range of different projects:

  • The immune response to cancer

-The group study the innate, adaptive and stromal response in several human cancers including leukaemia & lymphoma as well as pancreatic, ovarian and testicular cancer. Important technologies include flow sorting, CyTOF and single cell RNA-Seq.

  • Immune control of chronic human viral infection

- With over 20 years of contribution within cytomegalovirus infection, the team continue to investigate the mechanisms and impact of chronic viral infection on human health.

  • Mechanisms of graft-versus-leukaemia following stem cell transplantation

- Stem cell (bone marrow) transplantation can cure chemo-resistant cancer and the team are working with colleagues within the Department of Haematology to uncover the mechanisms of this effect

  • The Immunology of pregnancy

Pregnancy offers a major immunological challenge to the mother and several disorders of pregnancy may arise from a heightened fetal-specific ‘rejection’. In collaboration with Professor Kilby, the team investigate the underlying mechanisms of immune homeostasis.

Additional research is undertaken with Professor Stankovic on the genetics of Chronic Lymphocytic Leukaemia and with colleagues within UHBFT on research using Clinical Informatics.

His work is supported by four research Programme Grants and collaborations with Industry. Several of his discoveries have been taken into clinical trials.

He has been appointed as a member of the UoA1 panel (Clinical Medicine) in REF 2021.

He is on the Scientific Advisory Board for the MRC/LSHTM Unit in Uganda and the MATWIN cancer funding board in France.  

Other activities

Clinical Activity/NHS Affiliation 

Professor Moss is an honorary Consultant at the University Hospitals Birmingham NHS Foundation Trust. His primary interests are in haemato-oncology and general haematology and he is the Clinical Service Lead for Chronic Lymphocytic Leukaemia. He became an NIHR Senior Investigator in 2018.

He is currently Chair of the Grants Advisory Panel at Prostate Cancer UK, Chair of the Epidemic Technical Advisory Panel at the Wellcome Trust and a member of Innovate/MRC Biomedical Catalyst Major Awards Panel.

In addition he has previously held a number of important academic appointments:

- Chair of the Infections and Immunity Board and member of Strategy Board at the Medical Research Council

- Chair of the Cancer Research UK (CRUK) Clinical and Translational Research Committee (2008-2012)

- Member of the Wellcome Trust Clinical Interview Committee

- Deputy Chair of the MRC Infections and Immunity Board 2009-2013

- Output assessor for Clinical Medicine Panel of Research Excellence Framework 2014 (REF2014)

Professor Moss is also a member of the Scientific Advisory Board of Cell Medica.


Chanan-Khan, A., Cramer, P., Demirkan, F., Fraser, G., Silva, R.S., Grosicki, S., Pristupa, A., Janssens, A., Mayer, J., Bartlett, N.L., Dilhuydy, M., Pylypenko, H., Loscertales, J., Avigdor, A., Rule, S., Villa, D., Samoilova, O., Panagiotidis, P., Goy, A., Mato, A., Pavlovsky, M.A., Karlsson, C., Mahler, M., Salman, M., Sun, S., Phelps, C., Balasubramanian, S., Howes, A., Hallek, M.  Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study for the HELIOS investigators.  Lancet OncolFeb;17(2):200-11 (2016). 

Pachnio, A., Ciaurriz, M., Begum, J., Lal, N., Zuo, J., Beggs, A. & Moss, P.  Cytomegalovirus Infection Leads to Development of High Frequencies of Cytotoxic Virus-specific CD4+ T Cells Targeted to Vascular Endothelium. PLoS Pathogens, Sep 8;12(9) (2016).

Zuo, J., Willcox, C.R., Mohammed, F., Davey, M., Hunter, S., Khan, K., Antoun, A., Croudace, J., Inman, C., Parry, H., Briggs, D., Malladi, R., Willcox, B.E. & Moss, P.A.H.  A disease-linked ULBP6 polymorphism inhibits NKG2D-mediated target cell killing by enhancing the stability of NKG2D-ligand binding.  Science Signaling May 30;10(481) (2017).

Duchene, J., Novitzky-Basso, I., Thiriot, A., Casanova-Acebes, M., Bianchini, M., Etheridge, S.L., Hub, E., Nitz, K., Artinger, K., Eller, K., Caamano, J., Rulicke, T., Moss, P., Megens, R.T.A., von Andrian, U.H., Hidalgo, A., Weber, C., Rot, A.  Atypical chemokine receptor 1 on nucleated erythroid cells regulates hematopoiesis.  Nat Immunol.  Jul;18(7):753-761 (2017).

Powell, R.M., Lissauer, D., Tamblyn, J., Beggs, A., Cox, P., Moss, P., Kilby, M.D.  Decidual T Cells Exhibit a Highly Differentiated Phenotype and Demonstrate Potential Fetal Specificity and a Strong Transcriptional Response to IFN.  J Immunol. Nov 15; 199(10):3406-3417 (2017).

Maggs, L., Kinsella, F., Chan, Y.L.T., Eldershaw, S., Murray, D., Nunnick, J., Bird, J., Craddock, C., Zuo, J., Malladi, R., and Moss P. The number of CD56dim NK cells in the graft has a major impact on risk of disease relapse following allo-HSCT. Blood Adv. Aug 21;1(19):1589-1597 (2017).

Hosie, L., Pachnio, A., Zuo, J., Pearce, H., Riddell, S., Moss, P.  Cytomegalovirus-Specific T Cells Restricted by HLA-Cw*0702 Increase Markedly with Age and Dominate the CD8± T-Cell Repertoire in Older People.  Front Immunol. Dec 11;8:1776 (2017).

Inman, C. F., Eldershaw, S. A., Croudace, J. E., Davies, N. J., Sharma-Oates, A., Rai, T., Pearce, H., Sirovica, M., Chan, Y. L. T., Verma, K., Zuo, J., Nagra, S., Kinsella, F., Nunnick, J., Amel-Kashipaz, R., Craddock, C., Malladi, R. & Moss, P.  Unique features and clinical importance of acute alloreactive immune responses.  JCI Insight. May 17; 3 (10) (2018).

Zimmermann, M., Murina, O., Reijns, M.A.M., Agathanggelou, A., Challis, R., Tarnauskaite, Z., Muir, M., Fluteau, A., Aregger, M., McEwan, A., Yuan, W., Clarke, M., Lambros, M.B., Paneesha, S., Moss, P., Chandrashekhar, M., Angers, S., Moffat, J., Brunton, V.G., Hart, T., de Bono, J., Stankovic, T., Jackson, A.P., Durocher, D.  CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions.  Nature.  Jul4 (2018).

MD Morgan, CJ Day, KP Piper, N Khan, L Harper, P Moss, COS Savage (2010) Patients with Wegener's granulomatosis demonstrate a relative deficiency and functional impairment of T-regulatory cells.

G Chakupurakal, D Onion, M Cobbold, V Mautner, P Moss (2009) Adenovirus vector-specific T cells demonstrate a unique memory phenotype with high proliferative potential and coexpression of CCR5 and integrin alpha4beta7

S Nicholls, KP Piper, F Mohammed, TR Dafforn, S Tenzer, M Salim, P Mahendra, CF Craddock, P van Endert, H Schild, M Cobbold, VH Engelhard, P Moss, BE Willcox (2009) Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition
Proceedings of the National Academy of Sciences of the United States of America 106 3889-94

S Chidrawar, N Khan, W Wei, A McLarnon, N Smith, L Nayak, P Moss (2009) Cytomegalovirus-seropositivity has a profound influence on the magnitude of major lymphoid subsets within healthy individuals.
Clinical and experimental immunology 155 423-32

HM McGettrick, K Hunter, P Moss, CD Buckley, GE Rainger, GB Nash (2009) Direct observations of the kinetics of migrating T cells suggest active retention by endothelial cells with continual bidirectional migration
Journal of Leukocyte Biology 85 98-107


Cancer – especially immune response to cancer; immunity to viruses and related health problems; evolution in clinical medicine

Alternative contact number available for this expert: contact the press office